Abiopharma

🔍 Corkrean John J (Executive)

Company: FULLER H B CO (FUL)

Report Date: 2026-01-16

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-16 | Code: H | shares_owned_after: 54,646.00
• Acquired 200 shares of Phantom Units (Derivative)
  Date: 2026-01-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 28,248.05 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3
• Holds 41,208 shares of Employee Stock Option (Right-to-Buy) at $45.05 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2029-01-24 | Exercise: 2020-01-24 | shares_owned_after: 41,208.00 | Footnotes: F4
• Holds 48,309 shares of Employee Stock Option (Right-to-Buy) at $48.35 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2030-01-24 | Exercise: 2021-01-24 | shares_owned_after: 48,309.00 | Footnotes: F4
• Holds 23,696 shares of Employee Stock Option (Right-to-Buy) at $50.1 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2027-01-26 | Exercise: 2018-01-26 | shares_owned_after: 23,696.00 | Footnotes: F4
• Holds 38,376 shares of Employee Stock Option (Right-to-Buy) at $51.89 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2031-01-27 | Exercise: 2022-01-27 | shares_owned_after: 38,376.00 | Footnotes: F4
• Holds 21,834 shares of Employee Stock Option (Right-to-Buy) at $53.57 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2028-01-25 | Exercise: 2019-01-25 | shares_owned_after: 21,834.00 | Footnotes: F4
• Holds 24,570 shares of Employee Stock Option (Right-to-Buy) at $64.28 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2035-01-27 | Exercise: 2026-01-27 | shares_owned_after: 24,570.00 | Footnotes: F5
• Holds 22,312 shares of Employee Stock Option (Right-to-Buy) at $68.17 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2033-01-24 | Exercise: 2024-01-24 | shares_owned_after: 22,312.00 | Footnotes: F5
• Holds 21,997 shares of Employee Stock Option (Right-to-Buy) at $72.94 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2032-01-24 | Exercise: 2023-01-24 | shares_owned_after: 21,997.00 | Footnotes: F4
• Holds 24,774 shares of Employee Stock Option (Right-to-Buy) at $77.72 per share (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2034-01-26 | Exercise: 2025-01-26 | shares_owned_after: 24,774.00 | Footnotes: F5
• Holds 1,302 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2026-01-24 | Exercise: 2024-01-24 | shares_owned_after: 1,302.35 | Footnotes: F6, F7, F8
• Holds 2,853 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2027-01-26 | Exercise: 2025-01-26 | shares_owned_after: 2,852.64 | Footnotes: F6, F7, F8
• Holds 4,371 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-16 | Code: H | Expires: 2028-01-27 | Exercise: 2026-01-27 | shares_owned_after: 4,370.58 | Footnotes: F6, F7, F8

Footnotes:

• F1: These units (acquired after 12-31-04) convert into shares of common stock on a 1-for-1 basis.
• F2: These units (acquired after 12-31-04) convert into shares of common stock upon the earlier of certain termination events as specified in the Key Employee Deferred Compensation Plan or such earlier date as selected by the participant, subject to holding periods required by law.
• F3: Amount includes stock units acquired pursuant to a dividend equivalent feature.
• F4: This option is 100% vested.
• F5: This option vests in three annual installments (33%, 33%, and 34%) beginning on the date shown.
• F6: These restricted stock units convert into shares of common stock on a 1-for-1 basis.
• F7: These restricted stock units vest in three annual installments (33%, 33%, and 34%) beginning on the date shown.
• F8: Amount includes restricted stock units acquired pursuant to a dividend equivalent reinvestment feature.